Neoadjuvant chemotherapy for cervical cancer application status.doc

 PAGE \* MERGEFORMAT 13 Neoadjuvant chemotherapy for cervical cancer application status [Keywords:] cervical cancer, antineoplastic combined chemotherapy protocols Cervical cancer is one of the most common gynecologic malignancy, the tumor is the most common causes of death among women [1]. In developing countries the incidence rate among women in the first, a great threat to the health of women. Cervical General treatment is surgery, radiotherapy or a combination of the two applications, although nearly 10 years to surgical techniques, radiotherapy equipment and technology is constantly improving, but there is no fundamental treatment of cervical cancer increased .5-year survival rates remain at 40% . In the past it was believed that cervical cancer is not sensitive to chemotherapy, especially cervical cancer are relatively insensitive to chemotherapy the tumor, chemotherapy only for advanced and recurrent patients in palliative care [2]. In recent years, the age incidence of cervical cancer tends to younger, and the proportion of adenocarcinoma increased retention of young patients required ovarian and sexual function was also higher, while traditional radiotherapy alone with radical surgery after preoperative radiotherapy results were better for squamous cell carcinoma, adenocarcinoma of the cervix not significantly improved survival rates, especially for bulky (tumor diametergt; = 4 cm and the treatment of locally advanced cervical cancer was not improved. In this regard, scholars of the chemotherapy of cervical cancer were more in-depth study, put forward and carry out a cervical cancer neoadjuvant chemotherapy (neoadjuvant chemotherapy, NACT, in order to improve the resection rate and radiation sensitivity, improve prognosis. 1 Definition of cervical cancer NACT Neoadjuvant chemotherapy (neoadjuvant chemotherapy, NACT is great for cervical cancer Ⅰ b local and locally advanced patients in the surgery and (or radiotherapy prior to chemotherapy.